Clinical trials: Blood Cancer
Chronic Hepatitis B Virus (HBV) Infection
New HBV Infection Biomarkers: Clinical Characterization and Impact on Management
Chronic Hepatitis B Virus (HBV) infection affects nearly 300 million people worldwide and is a leading cause of liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). In France, it affects around 0.3% of the population.
- Trial name
- HBV-Biomark (NCT06906016)
- Testing
- Collection of blood samples for the study of HBV biomarkers
- Where
- France
- Volunteers
- 900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Graft Versus Host Disease, Leukemia
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00002833
- Testing
- Filgrastim, Cladribine, Cyclosporine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancies
Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation
This study will determine the Maximal Tolerated Dose if any and the recommended dose for phase 2 of monalizumab, a monoclonal antibody directed against the CD94/NKG2A receptor, after allogenic stem cell transplantation.
- Trial name
- PIRAT (NCT02921685)
- Testing
- Monalizumab
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Institut Paoli-Calmettes
Patients With Chemotherapy Induced Anemia (CIA)
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 250 mg and 500 mg in patients suffering from Chemotherapy Induced anemia.
- Trial name
- PK-CIA-06 (NCT01280240)
- Testing
- Monofer(R)
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Pharmacosmos A/S
Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab…
- Trial name
- CAMMA 1 (NCT04910568)
- Testing
- Cevostamab, Tocilizumab, Pomalidomide
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 186 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma (MM)
A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple Myeloma
Multiple myeloma is the second most common hematologic malignancy in adults, and no curative treatment currently exists. With the development of monoclonal antibodies for tumor therapy, identifying tumor-specific biomarkers has…
- Trial name
- NCT06925958
- Testing
- Flow cytometry
- Volunteers
- 15 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002678
- Testing
- dexamethasone, melphalan, prednisone
- Where
- 37 sites in United States, Canada
- Volunteers
- 595 people
- Sponsor
- NCIC Clinical Trials Group
PCOS
Exogenous Ketone Supplementation in Females with Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) affects 1 in 5 females of reproductive age. Commonly characterized as a disorder of infertility, PCOS is often accompanied by 3 potent cardiovascular disease (CVD) risk factors: insulin…
- Trial name
- NCT06155708
- Testing
- Ketone, Water
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- McGill University
Neoplasms
Measuring Alterations of DNA in Human Blood
The purpose of this research is to evaluate an automated, laser-based technique for measuring DNA damge resulting from radiation.
- Trial name
- NCT00178308
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Rochester
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
The purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.
- Trial name
- NCT01042717
- Testing
- Plerixafor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Shi, Patricia, M.D.
Multiple Myeloma
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with…
- Trial name
- NCT01456689
- Testing
- LGH447, midazolam
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Hematological Malignancies
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
This is a long-term follow-up study for participants treated with Galapagos (GLPG) CAR T-cell therapies to evaluate the long-term safety and efficacy of GLPG CAR T-cell products for 15 years post infusion.
- Trial name
- Hesperia (NCT06652633)
- Testing
- GLPG CAR T-cell therapy
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 546 people
- Sponsor
- Lakefront Biotherapeutics NV
Leukemia
Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation
Hematopoietic stem cell transplantation (HSCT) is one of the best, and sometimes the only, option for the treatment of leukemia.
- Trial name
- NCT01517347
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking University People's Hospital
Leukemia
A Study for Leukemia Patients With Life-Threatening Infections
The goal of this clinical research study is to compare the effectiveness of a white blood cell transfusion with radiated cells to a white blood cell transfusion with cells that have not been radiated.
- Trial name
- NCT00968838
- Testing
- White Blood Cell Transfusion
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Trial name
- NCT00020176
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Refractory Multiple Myeloma
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.
- Trial name
- NCT04519476
- Testing
- Selinexor, Lenalidomide, Methylprednisolone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Oncotherapeutics
Hematological Malignancies
Study of ABT-751 in Patients With Refractory Hematologic Malignancies
ABT-751 is a new antitumor drug that that interferes with cell division. The goal of this clinical research study is to find the highest safe dose of ABT-751 that can be given as a treatment for refractory hematologic…
- Trial name
- NCT00047489
- Testing
- ABT-751
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Multiple Myeloma
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells (HSPC) in the bone marrow.
- Conditions
- Lymphoma, Multiple Myeloma, Leukemia
- Trial name
- NCT04504526
- Testing
- 68Ga-Pentixafor
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Frailty, Multiple Myeloma
ICOPE Program Feasibility in the Management of Myeloma Patients
This project proposes to adapt monthly the existing ICOPE (Integrated Care for Older People) MONITOR program for elderly myeloma patients. This adaptation aims to detect earlier functional decline and prevent loss of autonomy.
- Trial name
- Onco-ICOPE (NCT06247189)
- Testing
- ICOPE Monitoring
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute